In many cases, the ultimate therapeutic effect and design goals of the drug will vary. For example, Viagra developed by Pfizer Pharmaceuticals was originally aimed at treating cardiovascular diseases, but it was very popular on the market because of its completely different efficacy. If pharmaceutical companies can upgrade robotic microscope technology and image processing software one step at a time, and find potential new drug targets through experiments at the same time, this is undoubtedly helpful to them in precision pharmaceuticals.
Recursion PharmaceuTIcals is a company that uses computer vision technology to process cell images, and analyzes the characteristics of cells to evaluate the results of disease cell drug response.
They use advanced imaging technology and artificial intelligence technology to conduct high-throughput cell model experiments, and are committed to testing thousands of drug candidates in cell models of hundreds of diseases, and finally find new drugs corresponding to different diseases.
According to Arterial Network, the company can perform extraordinary and detailed examination of cells. They used the software to determine thousands of characteristics of a cell, such as the size and shape of the nucleus or the distance between different regions within the cell. This sophisticated cell research not only promotes the medical industry's recognition, exploration and diagnosis of diseases, but also accelerates the transformation of the pharmaceutical model and greatly benefits patients.
It is not uncommon for companies that use the microscopic image characteristics of cells for drug screening, and Recursion PharmaceuTIcals is unique in that it combines machine automation and artificial intelligence technology to parallelize multiple experiments on a large scale. Now, Recursion's laboratory can conduct 30,000 experiments per week. Dr. Chris Gibson, CEO of Recursion believes that they can conduct hundreds of thousands of experiments per week in the near future.
Studies have shown that about 10% of Americans suffer from rare diseases, most of which stem from the lack of corresponding treatments.
Recursion PharmaceuTIcals said they have identified 15 drug candidates for treating rare diseases (meaning diseases with fewer than 200,000 patients in the United States). Most of these diseases are genetic diseases, and nearly 7,000 rare diseases are currently registered.
Recursion PharmaceuTIcals was established in 2013 in Salt Lake City, Utah, USA. In June 2018, the company has received a $20 million credit loan from Square 1 Bank.
Team strength to achieve precise treatmentDr. Gibson, Co-founder and CEO of Recursion Pharmaceuticals, said the company is working hard to achieve precision treatment through cooperation. He firmly believes that the collection and application of high-control, high-organization biological data is the core of achieving this goal.
In 2005, Chris Gibson received a Bachelor of Arts in Management Studies and a Bachelor of Science in Bioengineering and Biomedical Technology from Rice University. In 2009, Chris Gibson began his Ph.D. studies in bioengineering and medicine at the University of Utah in the United States, and received a degree certificate in 2013.
During the study, Dr. Gibson mainly carried out cardiovascular studies in engineering and biology. With the assistance of mentor Dr. Dean Li, he established an analysis system to improve the efficiency of new biometrics, laying the foundation for the later entrepreneurial foundation of Recursion Pharmaceuticals.
In 2013, Dr. Gibson received an Ignite certificate at the Stanford Graduate Business School. The Stanford University Ignite Certificate is an academic program for entrepreneurs, businessmen, and entrepreneurial leaders. Participants can learn business-related skills and gain experience in commercializing new businesses.
In addition, Dr. Gibson is also a member of CureHHT's board of directors. HHT is called hereditary hemorrhagic telangiectasia, a genetic disease that causes vascular malformations in multiple organs. The CureHHT Foundation is also the only advocacy organization in the world focusing on patients with the disease.
As one of the scientific guidance of Recursion Pharmaceuticals, Dr. Yoshua Bengio once said: "Recursion uses deep learning to explore millions of high-resolution cell images. They have the potential and influence to promote the unprecedented medical breadth. Biological excavation."
Dr. Yoshua Bengio is a computer scientist from Quebec, Canada. He is committed to the research of artificial neural networks and deep learning, trying to understand the principles of artificial intelligence. As of September 2017, his research results have been cited more than 80,000 times on Google Scholar.
Dr. Bengio received a doctorate in computer science from McGill University in Canada in 1991. He was a postdoctoral researcher at MIT and AT&T Bell Labs. He and the British computer psychologist Geoffrey Hinton, the head of Facebook's artificial intelligence laboratory Yann LeCun jointly called the three giants in the field of neural networks.
Since 1993, he has taught at the University of Montreal as a faculty member, devoted himself to academics, trying to train thousands of scientists and engineers. At the same time, he is also the principal of the Montreal Institute of Learning Algorithms (MILA) and the co-director of the Machine and Brain Learning Program at the Canadian Advanced Research Institute.
In 2017, Dr. Bengio was awarded the Medal of Honor for Canadian Officials and was appointed a Fellow of the Royal Society of Canada. The Canadian Official Medal of Honor is one of the branches of the Canadian Medal, which is mainly awarded to members of society who have made outstanding contributions and services to the Canadian people. In the same year, he also won the Marie-Victorin Quebec Award.
Dr. Bengio is currently an editor of the Journal of Machine Learning Research, an associate editor of the Journal of Neural Computing, an editor of the Fundamentals and Trends of Machine Learning, and an associate editor of the Journal of Machine Learning and the IEEE Journal of Neural Networks.
As the co-founder and CEO of Recursion Pharmaceuticals, Dr. Chris Gibson has formulated the company's business strategy-by continuously positioning and exploring the drugs taken by patients with rare diseases, actively promoting innovative pharmaceuticals to obtain corresponding commercial value.
Dr. Gibson said: "The combination of experimental biology and bioinformatics will enable us to work more efficiently. At the same time, we are working hard to establish more partnerships in the pharmaceutical field with the aim of quickly realizing Recursion Pharmaceuticals' business strategy."
In November 2016, Recursion Pharmaceuticals received US$15 million in Series A investments. The investors were Felicis Venturs, Data Collective, AME Cloud Ventures, Lux Capital, EPIC Ventures and Obvious Ventures.
According to Recursion’s report, the financing will assist the company in developing the “platform 2.0â€. On the one hand, the number of rare diseases studied by researchers every year can rise from tens to thousands in the past. On the other hand, the new platform can help them understand the known drugs, biologically active compounds and those pharmaceutical assets that have been put on hold in the field of rare diseases.
In October 2017, Recursion Pharmaceuticals received a $60 million Series B investment. Investors included 10 venture capital companies led by Data Collective.
Dr. Gibson said that the round B financing strongly supported the company's continuous progress on the drug positioning road. They will use the funds to establish cooperation with large pharmaceutical companies, build internal treatment channels, and expand emerging treatment areas. Dr. Gibson firmly believes: "Recursion will continue to increase a large number of high-dimensional data sets on hundreds of millions of biological interference problems. At the same time, we will also be prepared to reliably carry out trillions of relationships between genes, proteins and chemicals. Biological analysis."
In November 2017, Recursion Pharmaceuticals announced a formal cooperation with Splunk. Recursion uses Splunk's technology to combine biological science and machine learning to analyze and compare data generated from thousands of cell culture pictures and trillions of DNA strands. Recursion Pharmaceuticals aims to achieve the treatment of 100 molecular genetic diseases by 2025.
Rick Fitz, senior vice president of IT marketing at Splunk, said that Splunk is very honored to help Recursion transform machine data into a cure for genetic diseases. Splunk provides machine learning capabilities in its solutions to fully tap the value of data, help companies solve problems, and in some cases even save lives.
Although Recursion Pharmaceuticals currently has no products on the market, it has 15 treatments for rare diseases in drug development. Co-founder and CEO Dr. Gibson said they found that some potential therapies have been used in clinical trials by other pharmaceutical companies.
"This is a frustrating thing from a profit perspective, but from a scientific perspective, it confirms the effectiveness of Recursion's technology," said Dr. Gibson. "We can use unique image analysis to effectively develop new therapies in the medical field."
Recursion's technology platform uses the latest biotechnology to build hundreds of cell models that simulate rare diseases, and takes photos of these cell models that simulate rare diseases through advanced imaging technology. Just as patients with rare diseases will show symptoms of the disease, cell models of rare diseases will also show specific features in the cell structure, and these features can be unearthed from micrographs.
During the study, Recursion's image analysis software will analyze the nearly 1,000 kinds of cell structure features on the micrograph to find out the cell features related to the disease. Then, based on the characteristics of these cells, the software helps researchers find therapies that can correct these cell characteristics in a database of 2,000 known compounds.
1. Chemical drugs lead the pharmaceutical industryRecursion Pharmaceuticals says their drug discovery includes targeting compounds that can reverse complex phenotypes and compounds that can remain active in orthogonal disease-specific assays. They used the company's characteristic technology to develop an "intelligent drug library" with the main purpose of maximizing functional diversity and conducting efficient parallel screening. The screening process is as follows:
-Recursion scans a variety of cell types that can generate high-latitude phenotype signals from the company's parent library, and at the same time, through research to determine the cell's movement mechanism and toxicity changes.
-Build an "intelligent drug library" based on the maximal characteristics of phenotype/functional diversity, which includes a small number of mother libraries, with the main purpose of improving the efficiency of drug screening. ï¼ Screen out the cells of the “smart drug library†from hundreds of disease models, and conduct research and in-depth experiments on them.
ï¼ Work out plans with partners to optimize cell series with high dimensionality and toxicity signals.
2. With drug discovery as the ultimate goalRecursion Pharmaceuticals conducts objective suppression gene screening across the genome, providing its partners with professional biological insights in hundreds of disease models. Recursion's molecular biologists and computer teams combine functional genomics and complex AI technologies in research projects to meet the needs of partners and carry out relevant target identification and verification.
"There is a lot of hype in the current AI field, and what many people promise will not come true," stressed co-founder and CEO Dr. Gibson. "But there are some real opportunities in the industry that can enhance the industry and help it evolve. With the use of computer engines, this industry will be rapidly developed and improved."
The current series of progress is exciting, and Dr. Gibson looks forward to a four-fold increase in the success rate of clinical new drugs when he is 60 years old. Such success will further promote new business models and form a positive cycle in the pharmaceutical industry.
Guangzhou Yunge Tianhong Electronic Technology Co., Ltd , https://www.e-cigarettesfactory.com